OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Goulart on the Efficacy of Frontline Blinatumomab Plus Ponatinib in Ph+ B-ALL

December 7th 2025

Hannah Goulart, MD, discusses the use of first-line blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML

December 7th 2025

Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, discusses the efficacy of revumenib plus decitabine, cedazuridine, and venetoclax in newly diagnosed AML.

Dr Scanlon on the Incidence, Management, and Physiologic Impact of IVC Tumor Thrombus in RCC

December 6th 2025

Lorraine Scanlon, MD, discusses IVC tumor thrombus in RCC, its management, and how relieving venous congestion may improve renal function and guide future care.

Dr Li on Progression Risk in Low-Grade NMIBC and the Emerging Role of AI-Based Pathology Assessment

December 6th 2025

Roger Li, MD, discusses progression risk in low-grade NMIBC and how AI-based pathology tools may improve identification of patients at risk for high-grade disease.

Dr Desai on Future Research Directions in MPN and Other Hematologic Malignancies

December 5th 2025

Ruchi J. Desai, MD, discusses future research directions in MPN and other hematologic malignancies.

Dr George on Early Insights and Future Directions for Water Vapor Thermal Therapy in Prostate Cancer

December 5th 2025

Arvin K. George, MD, discusses the mechanism of water vapor thermal therapy and the implications of VAPOR 2 findings in prostate cancer management.

Dr Lyon on Logistical and Clinical Challenges Associated With Intravesical Therapy for NMIBC

December 5th 2025

Timothy D. Lyon, MD, discuss logistical and clinical challenges faced by patients with non–muscle-invasive bladder cancer who undergo intravesical therapy.

Dr Smith on the Role of Radioligand Therapy in Prostate Cancer

December 4th 2025

Matthew R. Smith, MD, PhD, discusses how radioligand therapies are altering the prostate cancer treatment paradigm.

Dr Randall on the Multidisciplinary Foundation of Research Into Sarcoma Survivorship

December 4th 2025

R. Lor Randall, MD, FACS, discusses the multidisciplinary nature of research aiming to develop a predictive model of sarcoma survivorship.

Dr Bellmunt on Future Directions With ctDNA-Guided Immunotherapy in Urothelial Cancer

December 3rd 2025

Joaquim Bellmunt, MD, PhD, discusses future research directions with ctDNA-guided immunotherapy in urothelial cancer.

Dr Jänne on the Design of the FLAURA2 Trial of Osimertinib Plus Chemotherapy in EGFR+ NSCLC

December 3rd 2025

Pasi A. Jänne, MD, PhD, discusses the design of the FLAURA2 trial in EGFR+ NSCLC.

Dr Raab on Continued Investigation of Teclistamab Plus Daratumumab-Based Induction in Myeloma

December 2nd 2025

Marc S. Raab, MD, discusses future avenues for the investigation of teclistamab plus daratumumab-based induction regimens in newly diagnosed multiple myeloma.

Dr Freedland on the Increasingly Prominent Role of Enzalutamide in Prostate Cancer Treatment

December 1st 2025

Stephen Freedland, MD, discusses how findings from the phase 3 EMBARK trial suggest a new standard of care in prostate cancer.

Dr Desai on the Use of JAK Inhibitors in Myeloproliferative Neoplasms

November 28th 2025

Ruchi J. Desai, MD, discusses the current standing of JAK inhibitors in the treatment landscape of myeloproliferative neoplasms.

Dr Smith on Future Research Directions in Prostate Cancer

November 28th 2025

Matthew R. Smith, MD, PhD, discusses what the future of prostate cancer research may look like.

Dr Jakubowiak on the Efficacy of KRd Maintenance Therapy Post-ASCT in Multiple Myeloma

November 28th 2025

Andrzej Jakubowiak, MD, PhD, discusses efficacy data with maintenance KRd after ASCT in multiple myeloma.

Dr Bellmunt on Adjuvant Atezolizumab in Patients With MIBC Who Were ctDNA+ After Initial Testing

November 28th 2025

Joaquim Bellmunt, MD, PhD, discusses subgroup and safety data from the phase 3 IMvigor011 trial in patients with MIBC.

Dr Gonzalez-Martin on the NAPISTAR1-01 Trial of TUB-040 in Ovarian Cancer

November 28th 2025

Antonio Gonzalez-Martin, MD, discusses the design of the NAPISTAR1-01 trial of TUB-040 in ovarian cancer.

Dr Randall on the Importance of Addressing Socioeconomic Disparities to Improve Sarcoma Survivorship

November 27th 2025

R. Lor Randall, MD, FACS, discusses the potential implications of research into how socioeconomic disparities and cancer biology impact long-term outcomes in pediatric sarcoma.

Dr Leal on Clinical Considerations Surrounding the Diagnosis of LEMS in Patients With Lung Cancer

November 26th 2025

Ticiana Leal, MD, discusses clinical considerations surrounding the diagnosis of LEMS in patients with lung cancer.